Your browser doesn't support javascript.
loading
Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells.
Matas-Rico, Elisa; Frijlink, Elselien; van der Haar Àvila, Irene; Menegakis, Apostolos; van Zon, Maaike; Morris, Andrew J; Koster, Jan; Salgado-Polo, Fernando; de Kivit, Sander; Lança, Telma; Mazzocca, Antonio; Johnson, Zoë; Haanen, John; Schumacher, Ton N; Perrakis, Anastassis; Verbrugge, Inge; van den Berg, Joost H; Borst, Jannie; Moolenaar, Wouter H.
Afiliação
  • Matas-Rico E; Division of Biochemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: ematas@uma.es.
  • Frijlink E; Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
  • van der Haar Àvila I; Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
  • Menegakis A; Oncode Institute, Utrecht, the Netherlands; Division of Cell Biology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • van Zon M; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Morris AJ; Division of Cardiovascular Medicine, Gill Heart Institute and Lexington Veterans Affairs Medical Center, University of Kentucky, Lexington, KY, USA.
  • Koster J; Laboratory for Experimental Oncology and Radiobiology, Amsterdam UMC, Amsterdam, the Netherlands.
  • Salgado-Polo F; Division of Biochemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
  • de Kivit S; Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
  • Lança T; Oncode Institute, Utrecht, the Netherlands; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Mazzocca A; Interdisciplinary Department of Medicine, University of Bari School of Medicine, Bari, Italy.
  • Johnson Z; iOnctura SA, Campus Biotech Innovation Park, Geneva, Switzerland.
  • Haanen J; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Schumacher TN; Oncode Institute, Utrecht, the Netherlands; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Perrakis A; Division of Biochemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
  • Verbrugge I; Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
  • van den Berg JH; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Borst J; Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands. Electronic address: j.g.borst@lumc.nl.
  • Moolenaar WH; Division of Biochemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: w.moolenaar@nki.nl.
Cell Rep ; 37(7): 110013, 2021 11 16.
Article em En | MEDLINE | ID: mdl-34788605
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos do Interstício Tumoral / Diester Fosfórico Hidrolases Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos do Interstício Tumoral / Diester Fosfórico Hidrolases Idioma: En Ano de publicação: 2021 Tipo de documento: Article